
{"id":1279,"date":"2026-07-20T23:30:33","date_gmt":"2026-07-20T23:30:33","guid":{"rendered":"https:\/\/everlong.mediablizz.com\/?post_type=product&#038;p=1279"},"modified":"2026-08-03T18:40:57","modified_gmt":"2026-08-03T18:40:57","slug":"tirzepatide-10mg","status":"publish","type":"product","link":"https:\/\/everlong.mediablizz.com\/index.php\/product\/tirzepatide-10mg\/","title":{"rendered":"TIRZEPATIDE &#8211; 10MG"},"content":{"rendered":"<p><strong>Tirzepatide is a double glucagon hormone receptor agonist (GLP-1 and GIP receptors), making it more effective for body fat mass reduction than its predecessor Semaglutide (Ozempic) by targeting further receptors.<\/strong><\/p>\n<p><strong>The peptide incorporates a C20 fatty diacid moiety via a \u03b3Glu-(AEEA)\u2082 linker enabling reversible albumin binding and an extended pharmacokinetic profile compatible with once-weekly dosing.<\/strong><\/p>\n<p><strong>It is the first dual GIP \/ GLP-1 receptor agonist approved by the FDA (Mounjaro\u00ae 2022, Zepbound\u00ae 2023) and serves as the reference compound for the broader class of multi-incretin analogs.<\/strong><\/p>\n<h4><strong>Benefits (Research Focus)<\/strong><\/h4>\n<ul>\n<li><strong>Dual receptor agonism \u2014 studied for simultaneous activation of GIP and GLP-1 receptors with imbalanced biased agonism<\/strong><\/li>\n<li><strong>Glycemic control research \u2014 investigated for fasting glucose, HbA1c, and insulin sensitivity parameters in T2D models<\/strong><\/li>\n<li><strong>Body composition \u2014 examined for fat-mass and lean-mass partitioning in obesity models<\/strong><\/li>\n<li><strong>Gastric emptying \u2014 explored for delayed gastric transit and downstream satiety endpoints<\/strong><\/li>\n<li><strong>Long-acting profile \u2014 C20 fatty diacid albumin-binding chemistry for extended half-life (~5 days)<\/strong><\/li>\n<\/ul>\n<h4><strong>\u26a0\ufe0f Disclaimer<\/strong><\/h4>\n<ul>\n<li><strong>This product is intended for laboratory research use only.<\/strong><\/li>\n<li><strong>Not for human or veterinary use.<\/strong><\/li>\n<li><strong>Not approved for diagnostic, therapeutic, or medical applications.<\/strong><\/li>\n<li><strong>Handle using appropriate laboratory safety procedures and personal protective equipment.<\/strong><\/li>\n<\/ul>\n<h4><strong>****** ON SALE DUE TO FACTORY ERROR ******<\/strong><\/h4>\n<p><strong>****** ORDERED AS RETATRUTIDE &#8211; RECEIVED AND TESTED AS TIRZEPATIDE ******<\/strong><\/p>\n<p><strong>****** 99.53% PURITY TIRZEPATIDE &#8211; SEE NOTES ON COA REPORT ******<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tirzepatide is a double glucagon hormone receptor agonist (GLP-1 and GIP receptors), making it more effective for body fat mass reduction than its predecessor Semaglutide (Ozempic) by targeting further receptors. The peptide incorporates a C20 fatty diacid moiety via a \u03b3Glu-(AEEA)\u2082 linker enabling reversible albumin binding and an extended pharmacokinetic profile compatible with once-weekly dosing. [&hellip;]<\/p>\n","protected":false},"featured_media":1306,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[18,26,17],"product_tag":[60,46,47,48,58,44,45,68,69,70],"class_list":["post-1279","product","type-product","status-publish","has-post-thumbnail","product_cat-metabolic","product_cat-on-sale","product_cat-weight_loss","product_tag-fat-lypolosis","product_tag-glp","product_tag-glp-1","product_tag-glucagon","product_tag-metabolic","product_tag-reta","product_tag-retatrutide","product_tag-tirz","product_tag-tirzepatide","product_tag-weight-loss","first","instock","sale","taxable","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/product\/1279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/comments?post=1279"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/media\/1306"}],"wp:attachment":[{"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/media?parent=1279"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/product_brand?post=1279"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/product_cat?post=1279"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/everlong.mediablizz.com\/index.php\/wp-json\/wp\/v2\/product_tag?post=1279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}